Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
ROCKVILLE, Maryland and EDMONTON, Alberta, and South San Francisco, California, March 30, 2026 – Aur...
Publisher
Canada
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
ROCKVILLE, Maryland and EDMONTON, Alberta, and South San Francisco, California, March 30, 2026 – Aur...
Source route
Continue on auriniapharma.com
Leave the platform to read the original full article on the publisher site.
Source: Aurinia Pharmaceuticals
Scope: Industry
Related coverage
More related coverage
CANOPY GROWTH’S APOLLO CANNABIS CLINICS NAMED BEST MEDICAL CANNABIS CLINIC
Voted best by Toronto Star Readers’ Choice Awards SMITH FALLS, ON, March 30, 2026 – Canopy Growth Co...
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Nestlé introduces an innovative complete nutritional solution for children with special medical nutr…
EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
Sobi® (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indicati...